Thrombophlebitis
|
A common disease that affects veins is
thrombophlebitis – which is an inflammation of the veins due to
blood clotting. A number of studies show that Wobenzym®
is very effective in decreasing
the pain, edema and throphic ulcers often seen in
thrombophlebitis and post-thrombophlebitis syndrome. The
studies show improvement of blood flow with increased blood
fibrinolytic activity and inhibited platelet function. In a randomized double blind phase III clinical trial they noted that after 15 days of treatment, there was a significant difference in favor of the enzyme treatment when pain, redness, swelling and induration ( a hardening of the tissue due to swelling and inflammation). We see the same improvement in lymphedema. From FREQUENTLY ASKED QUESTIONS, with answers by Joseph J Collins, RN, ND Read the special section: : CARVIOVASCULAR AND LYMPHATIC SYSTEMS & WOBENZYM® |
What the literature says about Systemic Enzyme Support and:
Thrombophlebitis
& Postthrombophlebitic Syndrome
Application of Wobenzym and Phlogenzym to the angiology and vascular
surgery.
Kopadze, T.Sh., Natsvlishvili, G.A., Tvaladze,
M.G., Avazashvili, D.N. Application of Wobenzym and Phlogenzym to
the angiology and vascular surgery. Georgian Medical News 2001, No.
2, (serial No.71), pp. 27 – 29. Department of Vascular and Urgent
microsurgery of the Tbilisi State Medical Academy for Post-Diploma
Education [Abstract in Russian]
In
1997-99 enzymotherapy was used in complex treatment of the 150
patients, that were admitted to the clinic of Vascular and Urgent
microsurgery of the Tbilisi First City Hospital. 83 of these
patients had disease of venous system, including acute
thrombophlebitis and postthrombophlebitic syndrome. We had used
enzymotherapy with Wobenzym and Phlogenzym in such cases and observe
decrease of pain, reduction of edema and throphic ulcers. The same
drugs were used in the treatment of arterial pathology (in 25
patients) with positive clinical outcomes.
We
also used enzymotherapy in treatment of 42 patients with different
traumas of the hand. After application of enzymes in such cases,
decrease of pain, reduction of edema and improvement of
microcirculation of the injured site were observed.
Basing on our experience we conclude, that enzymes, as medical means
with high efficacy and practical absence of adverse reactions, must
be widely used in the complex treatment of vascular and traumatic
disorders.
Key
words: enzymotherapy, Wobenzym, Phlogenzym, vascular and traumatic
disorders.
Systemic enzyme therapy of lower limb postphlebitic syndrome.
Koshkin V.M., Kirienko A.I., Leontjev S.G.,
Agafonov V.F. Systemic enzyme therapy of lower limb postphlebitic
syndrome. Angiology and
vascular surgery 2000, Vol. 6, No. 2, pp. 61 – 64.
Large clinical material (66 patients) and modern diagnostic
modalities were used for comparative study of systemic enzyme
therapy (Phlogenzym, 2 dragees per 3 times per day for 3 months) and
conventional combined therapy of lower limb postphlebitic syndrome.
Clinical effect of systemic enzyme therapy was more pronounced (84%
for systemic enzyme therapy vs 73% for conventional therapy). Better
outcome was provided by significant changes in hemostasis and blood
rheological parameters, especially by increased blood fibrinolytic
activity and inhibited platelet function. These resulted in
facilitation of venous outflow from affected extremity and clinical
regression of chronic venous insufficiency.
Key words: systemic & enzyme therapy, postphlebitic syndrome,
hemostasis, blood rheology, venous outflow.
Wobenzym in the treatment of Thrombophlebitis.
Džupina A.1,
Džupinová M.2 Wobenzym in the treatment of
Thrombophlebitis. Praktická flebologie 1998, Roè. 7, è. 1, str.
28-30 (17-12-3)
Summary: We would like to emphasize, that Wobenzym therapy of 46
deep vein thrombosis patients treated for one year led to a
disappearing of followed subjective troubles and to the improvement
in objective duplex ultrasound findings . These facts allowed us to
omit the anticoagulation therapy in 20 patients. In the rest of 26
patients the therapy led to a reduction of the leg edema and to the
better centripetal stream monitored by duplex ultrasound as well as
to a reduction or vanishing of the subjective troubles of patients.
This means better quality of patient`s life. Therapy by proteolytic
enzyme preparations in this indication is, in our opinion, very
suitable. Its effect is to be verified by more extensive trials with
more patients.
Poster Reference Number 48.
Wobenzym® in the Treatment of Acute Thrombophlebitis
(MU-693204)
Summary: In a randomised double blind clinical trial phase III (acc.
to German Drug Law) with two parallel groups, it should be
demonstrated in patients with thrombo- or varicophlebitis whether
the enzyme preparation Wobenzym® reduces pain and edema
earlier than a placebo treatment.
119
patients with clinically verified acute thrombophlebitis or
varicophlebitis of a superficial vein of the lower extremity were
taken into this study. 60 patients received the enzyme preparation
and 59 placebo. The data of all patients was evaluable.
Primary investigator was Prof. Valery M. Koshkin, M.D., D.M.Sci.,
Angiology Laboratory, Department of Surgery, State Medical
University of Russia, Leninsky prospect, 8 Ia, Moscow, 117049 -
Russia.
The
patients received 10 tablets t.i.d. (= 30 tablets per day). The
therapy lasted 15 days.
At
baseline the patients were comparable with regard to age, sex,
height, weight and the symptoms pain, redness, induration, swelling,
sum score of the symptoms, length of the inflammatory vascular
process and time for refilling of the veins (p > 0.05,
Wilcoxon-Mann-Whitney-U-test).
The
main endpoint for statistical evaluation was the sum score of the
symptoms pain, redness, induration and swelling.
As
secondary criteria the other parameters for evaluation of the
efficacy like pain, redness, induration, swelling, length of the
inflammatory vascular process, smallest circumference supramalleolar,
largest calf circumference, knee circumference, circumference 15 cm
above the knee, time for refilling the veins (by light-reflexion-rheography),
the result of therapy and the subjective judgement of efficacy by
the physician and the patients were evaluated. Other secondary
criteria were the laboratory parameters (ESR, white blood cells,
platelets, AST, ALT, g-GT), the subjective judgement of tolerante,
and adverse events caused by the study therapy.
The
main endpoint - the sum score of pain, redness, induration and
swelling - showed a statistically significant difference on the 5%
level (p = 0.033) after 15 days of treatment in favor of the enzyme
treatment.
The
judgement of the secondary criteria showed statistically significant
differences in favor of the enzyme treatment with pain (p = 0.033),
the length of the inflammatory vascular process (p = 0.005) and the
time for refilling the veins of the affected leg (p = 0.005).
The
result of therapy in the enzyme group was on average 2.6 ("good" to
"moderate") and therefore some better than in the placebo group with
3.0 ("moderate"), but the difference was not statistically
significant (p > 0.05).The efficacy of the drug was judged by the
physician at the end of therapy in the enzyme group with 2.6 ("good"
to "moderate") and in the placebo group with 2.9 ("moderate"). The
patients judged the efficacy as 2.6 ("good" to "moderate") in the
enzyme group and es 2.8 ("moderate") in the placebo group. The
differente between the groups was not statistically significant (p >
0.05).
The
tolerance of the therapy was judged by the physician in the enzyme
group as 1.8 ("good") and in the place- bo group as 1.7 ("very good"
to "good"). The judgement by the patients was similar: 1.9 ("good")
in the enzyme group and 1.8 ("good") in the placebo group. There was
no significant difference between the groups (p > 0.05).
Adverse events occurred in either group. Three were documented in
the enzyme group and four in the placebo group. The difference
between the groups was not statistically significant (p > 0.05). In
the enzyme group there was one thrombosis on the contralateral leg,
one deep vein thrombosis of the lower extremity and one acute
ileofemoral thrombosis. The onset was on average after 7.0 days and
they lasted for 7.3 days. The severity of all adverse events was
"moderate" and the cause judged as "unknown". In all three patients
the study therapy was stopped and twice a symptomatic therapy of the
adverse events with heparin was necessary. In two patients residual
complaints did not arise and the patient's outcome was without
damage. In one patient residual complaints without specification
were seen, there was a transitory damage. In the placebo group there
were dysphagia, nausea and headache. They started on average after
6.8 days, the duration was one day, and they were "moderate". They
were caused in one patient by the study drug, and in three cases the
cause was unknown. In one patient the therapy was stopped, in one
patient no measures were taken, and in two patients a symptomatic
therapy of the adverse event with analgesics was necessary. No
residual complaints were seen in any case, and all patients' outcome
was without damage.
Poster Reference Numb 49.